121 related articles for article (PubMed ID: 25003253)
21. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
22. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.
Pagano E; Borrelli F; Orlando P; Romano B; Monti M; Morbidelli L; Aviello G; Imperatore R; Capasso R; Piscitelli F; Buono L; Di Marzo V; Izzo AA
Pharmacol Res; 2017 May; 119():227-236. PubMed ID: 28193521
[TBL] [Abstract][Full Text] [Related]
24. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Talmadge JE; Hood KC; Zobel LC; Shafer LR; Coles M; Toth B
Int Immunopharmacol; 2007 Feb; 7(2):140-51. PubMed ID: 17178380
[TBL] [Abstract][Full Text] [Related]
25. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
26. Ghrelin administration suppresses inflammation-associated colorectal carcinogenesis in mice.
Kawaguchi M; Kanemaru A; Fukushima T; Yamamoto K; Tanaka H; Haruyama Y; Itoh H; Matsumoto N; Kangawa K; Nakazato M; Kataoka H
Cancer Sci; 2015 Sep; 106(9):1130-6. PubMed ID: 26094822
[TBL] [Abstract][Full Text] [Related]
27. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis.
Arguedas MR; Heudebert GR; Wilcox CM
Aliment Pharmacol Ther; 2001 May; 15(5):631-8. PubMed ID: 11328256
[TBL] [Abstract][Full Text] [Related]
28. Approach to angiogenesis inhibition based on cyclooxygenase-2.
Masferrer J
Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
[TBL] [Abstract][Full Text] [Related]
29. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potential targets of selenomethionine-mediated chemoprevention in colorectal carcinoma mouse model using proteomics analysis.
Rahman MM; Seo YR
Carcinogenesis; 2013 Jul; 34(7):1575-84. PubMed ID: 23504501
[TBL] [Abstract][Full Text] [Related]
31. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
[TBL] [Abstract][Full Text] [Related]
32. Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.
Kim JY; Chung SW; Kim SY; Byun Y
Pharm Res; 2015 Jul; 32(7):2318-27. PubMed ID: 25585956
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention of colorectal cancer: two steps forward, one step back?
Half EE; Arber N
Future Oncol; 2006 Dec; 2(6):697-704. PubMed ID: 17155896
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
35. Prevention of tumors of the large intestine by celecoxib in mice.
Coles M; Toth B
In Vivo; 2005; 19(4):661-5. PubMed ID: 15999531
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer.
Squires H; Tappenden P; Cooper K; Carroll C; Logan R; Hind D
Clin Ther; 2011 Sep; 33(9):1289-305. PubMed ID: 21840057
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Barnes MN; Chhieng DF; Dreher M; Jones JL; Grizzle WE; Jones L; Talley L; Partridge EE
Gynecol Oncol; 2005 Sep; 98(3):376-82. PubMed ID: 15993933
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib shown effective in preventing colon polyps.
Nelson NJ
J Natl Cancer Inst; 2006 May; 98(10):665-7. PubMed ID: 16705118
[No Abstract] [Full Text] [Related]
39. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
